Supplements

Acetyl-L-Carnitine (ALCAR)

Updated · 25 sources

Acetyl-L-carnitine (ALCAR, also called ALC, acetylcarnitine or levacecarnine) is L-carnitine with an acetyl group attached. The body makes it, and it is the most significant carnitine ester in mammals. It is sold mainly as a “brain” supplement and has been tested for depression, Alzheimer’s disease, mild cognitive impairment and nerve pain.

The most important fact is a safety finding. In a double-blind trial of 409 women receiving taxane chemotherapy for breast cancer, 3 g/day of ALCAR made nerve damage worse rather than better, and the difference was still measurable over two years. The American Society of Clinical Oncology (ASCO) now says its use to prevent chemotherapy neuropathy should be discouraged. In other settings the evidence is mixed: depression trials look positive but are weak, and the largest Alzheimer’s trials were negative.

This page covers what is specific to the acetyl form. For the biology, deficiency treatment and exercise research that apply to carnitine in general, see the Carnitine and L-Carnitine pages. This page summarizes what clinical trials, systematic reviews, a clinical guideline and the levocarnitine label report. It is for education only and is not medical advice.

Property Detail
Class Endogenous short-chain carnitine ester; dietary supplement ingredient
Formula and weight C₉H₁₇NO₄, 203.24 g/mol; hydrochloride salt 239.69 g/mol
Routes in cited studies Mostly oral; IV in a kinetics study
Doses in cited trials 1–3 g/day, usually divided, for 12 weeks to 12 months
Half-life After IV dosing in 11 people with Alzheimer’s disease: 0.073 h and 1.73 h (two phases). No oral half-life is listed here
Oral exposure Low. After 1.5 g, plasma acetylcarnitine rose from a median 9.4 to 12.5 µM, not statistically significant, in healthy adults
Main guideline position ASCO 2020: discouraged for preventing chemotherapy-induced neuropathy
US status Sold as a supplement; we found no FDA-approved acetyl-L-carnitine drug in Drugs@FDA. Levocarnitine is the approved carnitine drug
WADA status Not named on the 2026 Prohibited List; IV infusions over 100 mL per 12 h are a prohibited method

What it is

ALCAR is the ester formed when an acetyl group binds the hydroxyl group of L-carnitine (PubChem). It is the main carnitine ester in amount and function (Rebouche, Ann N Y Acad Sci 2004). It can supply both carnitine and an acetyl group. That acetyl group may, under the right conditions, feed the synthesis of acetylcholine, a neurotransmitter involved in memory (Krims-Davis et al., Mol Nutr Food Res 2025).

Proposed mechanisms include support for synapses, cholinergic activity, mitochondrial energy production and nerve-growth effects, but a 2020 review says the role of ALCAR in dementia “is still under debate” (Pennisi et al., Nutrients 2020). In rodents with depressive-like traits, it produced rapid antidepressant-like effects through histone acetylation, a form of gene regulation. This has not been shown directly in people (Nasca et al., PNAS 2018).

How it differs from L-carnitine

Feature Acetyl-L-carnitine L-carnitine
Structure Acetyl ester of carnitine, 203.24 g/mol Free carnitine, 161.20 g/mol
Carnitine content About 79% of ALCAR’s weight All of the free base; less in tartrate salts
Normal plasma level in the study below Median about 5–12 µM Median about 35–44 µM
Main research areas Depression, dementia, nerve damage Deficiency, muscle recovery, body composition
FDA-approved drug None found Levocarnitine (Carnitor)

Molecular weights are from PubChem and the Carnitor label; the carnitine fraction and plasma levels are from Krims-Davis et al. 2025. Some trials used the heavier hydrochloride salt, so stated weights may not be directly comparable (Thal et al., Neurology 1996).

Pharmacokinetics

Human data on the acetyl form are thin.

Absorption and clearance

Lab work suggests part of an oral dose is split into carnitine in the gut wall during absorption. Some gets through intact: 2 g/day raised circulating ALCAR by 43% (Rebouche 2004), reported elsewhere as a rise from 7.2 to 10.3 µM after 55 days (Pennisi et al. 2020). After a single 0.5 g IV dose, it is rapidly but incompletely converted to carnitine, and levels return to baseline within 12 hours. Its elimination resembles that of L-carnitine, and renal reabsorption becomes less efficient as blood levels rise (Rebouche 2004).

Direct comparison with L-carnitine

The most direct comparison is a 2025 set of open-label, single-dose studies in healthy volunteers, with 11–12 people analyzed per 1.5 g group (Krims-Davis et al. 2025):

Median plasma change after one dose 1.5 g ALCAR 1.5 g L-carnitine (labeled)
Acetylcarnitine 9.4 to 12.5 µM at 4 h (not significant) 12.1 to 20.9 µM at 4 h
Carnitine 35.3 to 43.9 µM at 16 h 44.4 to 60.9 µM at 8 h
TMAO 2.2 to 47 µM at 16 h 2.2 to 54.9 µM at 24 h
  • Lower exposure. The rise in plasma acetylcarnitine exposure after ALCAR was 7.7-fold lower than the rise in plasma carnitine exposure after carnitine. Comparing plasma carnitine exposure after each supplement, the gap was about 3-fold. These are different comparisons, which is why the numbers differ.
  • L-carnitine raised acetylcarnitine too. The total rise in plasma acetylcarnitine was not significantly different between the two 1.5 g doses. The authors think carnitine draws acetyl groups out of tissues for excretion, so this is not evidence that plain carnitine delivers more acetyl groups to the brain.
  • Net uptake was small. After estimated losses to gut bacteria and urine, the authors put remaining bioavailability under 5% of the dose. This net figure is calculated differently from the 15% absolute bioavailability on the Carnitor label.

The work was short (48 hours) and small, urine collection was incomplete, and repeated dosing was tested only with carnitine. The carnitine capsules also tested below label, delivering a measured 1,346 mg.

Reaching the brain

In 11 people with Alzheimer’s disease, cerebrospinal fluid (CSF) levels of ALCAR rose in parallel with plasma after 30 mg/kg IV for 10 days and then 1.5 g/day orally. The authors said this suggests ALCAR “easily crosses the blood-brain barrier” (Parnetti et al., Eur J Clin Pharmacol 1992). There was no L-carnitine comparison.

About “better absorbed” and “better brain penetration.” ALCAR is sometimes described as a superior form of carnitine. The only head-to-head human study we found showed lower plasma exposure than L-carnitine. We found no human study directly comparing how much of each form reaches the brain after oral dosing.

What the research shows

Depression

People with major depression had lower blood ALCAR, but not lower free carnitine, than matched controls at two study centers, and lower levels tracked with greater severity in exploratory analyses (Nasca et al. 2018). This cross-sectional result cannot show that low ALCAR causes depression or that replacing it helps.

Two meta-analyses have pooled the trials:

Analysis Trials and people Comparison Standardized mean difference (95% CI)
Veronese et al., Psychosom Med 2018 9 RCTs, 467 people Placebo or no intervention −1.10 (−1.65 to −0.56); I² 86%
Veronese et al. 2018 3 RCTs, 324 people Antidepressants 0.06 (−0.22 to 0.34); I² 31%
Kumar et al., Neuropsychiatr Dis Treat 2026 10 RCTs, 725 people Any control −1.20 (−2.12 to −0.29); I² 96.9%
Kumar et al. 2026 4 RCTs Placebo, ALCAR alone −2.41 (−4.43 to −0.39)
Kumar et al. 2026 Subgroup Another drug, head to head −0.19 (−0.84 to 0.45)

A standardized mean difference expresses the effect in standard deviations; negative values favor ALCAR. A value above 1 would be large, but these results should not be taken at face value:

  • Trials disagree widely. An I² near 97% means the trials differ far more than chance would explain.
  • Small-study effects. Kumar’s tests suggested them (Egger P under 0.001), and the authors said the overall certainty “would probably be low with high risk of publication bias.”
  • Benefit concentrated in older adults. In Kumar’s analysis, trials in people aged 60 or older had an effect of −1.88 (95% CI −3.26 to −0.50), while trials in mainly younger adults showed −0.28 (95% CI −0.77 to 0.20), which is not significant.
  • Head-to-head trials show no clear difference, not proven equivalence. The comparisons were few.

Mild cognitive impairment and Alzheimer’s disease

Early, small trials looked encouraging, including one positive year-long study in mild Alzheimer’s disease (Pennisi et al. 2020). The largest trials then did not confirm a benefit:

Study Who Regimen Result
Thal et al., Neurology 1996 431 people aged 50 or older with mild to moderate Alzheimer’s ALCAR hydrochloride 1 g three times daily vs placebo, 12 months Both groups declined at the same rate on primary measures. A post hoc analysis suggested those aged 65 or younger might do better and older patients worse
Thal et al., Neurology 2000 229 people aged 45–65 with early-onset Alzheimer’s 1 g three times daily vs placebo, 12 months Prospective test of the subgroup idea: “failed to slow decline.” Less MMSE decline in completers only
Hudson and Tabet, Cochrane 2003 11 double-blind trials, all in Alzheimer’s ALCAR vs placebo More global improvement at 12 weeks (OR 2.33; 95% CI 1.25–4.35) and 24 weeks (OR 3.91; 95% CI 1.32–11.54), not at 52 weeks. No benefit on cognition, severity or function
Montgomery et al., Int Clin Psychopharmacol 2003 Mild cognitive impairment and mild Alzheimer’s, trials of 3 months or longer 1.5–3 g/day vs placebo Summary effect size 0.20 (95% CI 0.11–0.30); clinician global impression 0.32 (95% CI 0.18–0.47)

The two 2003 reviews asked different questions. Montgomery combined many scales into one small positive summary, in a population that included milder patients. Cochrane looked at each outcome in Alzheimer’s disease, warned that its positive result “may be due to chance,” and concluded that ALCAR is not likely “to prove an important therapeutic agent.”

The mild cognitive impairment evidence rests largely on the Montgomery analysis, which a later review describes as 21 studies with 591 people on ALCAR and 613 on placebo. Older trials enrolled people described as having “mild mental impairment” or “mental decline,” and diagnostic criteria changed greatly over the 30 years covered (Pennisi et al. 2020). We found no large trial of ALCAR alone using current diagnostic criteria for mild cognitive impairment.

Alpha-GPC and citicoline have their own evidence pages.

Diabetic neuropathy

The 2019 Cochrane review, covering four trials with 907 participants, was “very uncertain” whether ALCAR reduces pain (Rolim et al., Cochrane 2019):

Outcome vs placebo (0–100 mm pain scale) Mean difference (95% CI) Trials, people
Pain, all doses −9.16 mm (−16.76 to −1.57) 3 trials, 540 people; very low certainty
Pain, 1,500 mg/day or less −0.05 mm (−10.00 to 9.89) 2 studies, 159 people
Pain, more than 1,500 mg/day −14.93 mm (−19.16 to −10.70) 3 studies, 381 people; lower certainty still

No trial reported the share of people achieving at least 30% or 50% pain relief, and none used validated symptom scales. Two trials were funded by an ALCAR manufacturer, and the other two had a co-author who consulted for one.

A separate analysis of two 52-week placebo-controlled trials covered 1,257 patients given 500 or 1,000 mg three times daily. Sural nerve biopsies showed more nerve fibers and regenerating clusters, and vibration sense improved. Nerve conduction did not improve. Pain improved significantly in one trial and in the combined 1,000 mg group (Sima et al., Diabetes Care 2005). The Cochrane abstract counts fewer placebo-controlled participants (675) than this report and does not explain the difference.

Alpha-lipoic acid has its own evidence in this condition.

Chemotherapy-induced neuropathy: the worsening signal

Earlier studies had suggested that ALCAR could prevent or treat this nerve damage. SWOG S0715 tested that in a double-blind trial of women receiving adjuvant taxane chemotherapy for breast cancer, using 1 g three times daily or placebo for 24 weeks. Neuropathy was scored on an 11-item patient-reported scale, where lower scores mean worse symptoms (Hershman et al., J Clin Oncol 2013):

Measure in S0715 (409 evaluable: 208 ALCAR, 201 placebo) ALCAR vs placebo
Score at 12 weeks, primary endpoint 0.9 points lower (95% CI −2.2 to 0.4; P = .17)
Score at 24 weeks 1.8 points lower (95% CI −3.2 to −0.4; P = .01)
Decline of more than 5 points 38% vs 28% (P = .05)
Grade 3–4 neurotoxicity 8 vs 1 patients

The harm lasted beyond treatment. In the two-year follow-up, ALCAR scores were lower overall by 1.39 points (95% CI −2.48 to −0.30; P = .01), including at week 36 (−1.37) and week 52 (−1.83). At week 104, 39.5% on ALCAR and 34.4% on placebo reported a five-point decline. This later regression analysis gives −1.68 for week 24, slightly different from the −1.8 in the first report (Hershman et al., J Natl Cancer Inst 2018). The authors called for work to understand the mechanism.

ASCO’s 2020 guideline update states that “the use of acetyl-l-carnitine for the prevention of CIPN in patients with cancer should be discouraged” (Loprinzi et al., J Clin Oncol 2020).

The harm has not been shown with every drug. In a smaller phase II trial of 150 patients with ovarian or prostate cancer receiving sagopilone, a different microtubule drug, ALCAR did not change overall neuropathy rates, and severe neuropathy was less common in the ovarian cancer subgroup (Campone et al., Oncologist 2013).

Male infertility

ALCAR is often studied with L-carnitine, so its separate contribution is hard to isolate.

Study Who Regimen Result
Balercia et al., Fertil Steril 2005 60 infertile men aged 20–40 with low motility L-carnitine 3 g/day, ALCAR 3 g/day, both (2 g + 1 g), or placebo, 6 months Sperm motility rose with ALCAR alone or combined; men with the lowest baseline values were most likely to respond
Sigman et al., Fertil Steril 2006 21 men with low motility L-carnitine 2 g + ALCAR 1 g/day vs placebo, 24 weeks No significant or clinically meaningful change in motility or total motile count

Both trials are small and measured semen quality, not births. A 2022 Cochrane review of oral antioxidants in general (20 types, 90 trials, 10,303 men), not ALCAR specifically, gives the wider picture. Live birth appeared more likely overall (OR 1.43; 95% CI 1.07–1.91; very low certainty), but the effect disappeared when trials at high risk of bias were removed (OR 1.22; 95% CI 0.85–1.75). The authors called the evidence inconclusive (de Ligny et al., Cochrane 2022). We found no trial of ALCAR alone that reported live births.

Muscle and exercise

Exercise research on carnitine mostly uses L-carnitine L-tartrate; see the L-Carnitine page. A PubMed search found no randomized trial of ALCAR for testosterone, muscle mass or resistance training.

Side effects and risks

Tolerability

In trials, ALCAR was generally well tolerated, apart from the taxane finding above:

  • Depression trials. Eleven of 15 trials reported adverse events. Rates of at least one event ranged from 0–35% on ALCAR and 10–46% in controls, mostly mild gastrointestinal or nervous system complaints, with no excess of serious events (Kumar et al. 2026).
  • Diabetic neuropathy. In one trial, 4.1% stopped because of adverse events on more than 1,500 mg/day vs 1.4% on placebo (P = .17). Reasons included headache, facial tingling and gut symptoms. Cochrane considered the safety evidence too uncertain for firm judgments (Rolim et al. 2019).
  • Dementia trials. Reported reactions included nausea, agitation, insomnia and increased appetite (Pennisi et al. 2020).

TMAO

Gut bacteria convert carnitine to trimethylamine, which the liver turns into TMAO (trimethylamine N-oxide), a proposed cardiovascular risk marker; see the L-Carnitine page. The acetyl form does not appear to avoid this.

In the 2025 comparison, 1.5 g of ALCAR raised median plasma TMAO from 2.2 to 47 µM, close to the rise from L-carnitine. Total TMAO exposure was 978 vs 1,191 µM·h, and the authors say the two align once ALCAR’s lower carnitine content is considered (Krims-Davis et al. 2025). Some points need context:

  • The “90%” figure. The authors estimated that up to 90% of the dose left the body as TMAO, from incomplete urine collections. The Carnitor label reports 8–49% of an oral radiolabeled carnitine dose recovered as TMAO, a different method and product. The exact share is uncertain, though both show substantial conversion.
  • A short-term peak. These are single-dose peaks. Sustained elevation was measured only with repeated carnitine.
  • Unknown clinical meaning. The authors note that a harmful TMAO level is undefined. We found no trial testing whether ALCAR affects heart attacks or strokes.

Thyroid

The thyroid concern comes from L-carnitine, not from trials of ALCAR. In a randomized trial of 50 women on a fixed suppressive dose of levothyroxine (thyroid hormone), L-carnitine 2 or 4 g/day reversed or prevented symptoms and lab changes of excess thyroid hormone. The authors describe carnitine as a peripheral antagonist of thyroid hormone, based on cell experiments showing it blocks hormone entry into the cell nucleus (Benvenga et al., J Clin Endocrinol Metab 2001).

For ALCAR itself, we found only laboratory work on enzyme inhibition and iodine binding, with no human data (Caro-Ramírez et al., Spectrochim Acta A 2024). Because ALCAR is converted partly to carnitine, an effect is plausible, but no human trial has tested its effect on thyroid function or levothyroxine treatment.

Warfarin and other label warnings

The levocarnitine label reports INR increases (a clotting-time measure) in people taking warfarin and recommends monitoring INR after starting or changing the dose. It also reports seizures in people with and without a seizure history, and warns that metabolites may build up with chronic high oral doses in severe kidney impairment or on dialysis (Carnitor label).

These warnings were written for levocarnitine. We found no study of ALCAR with warfarin. Since ALCAR is partly converted to carnitine, applying them to it is a reasonable precaution, but it is an extrapolation.

In the US, ALCAR is sold as a dietary supplement; we found no ALCAR product in Drugs@FDA.

ALCAR is not named on the WADA list. IV infusions or injections of more than 100 mL per 12 hours are prohibited as a method, regardless of substance, unless legitimately received during hospital treatment, surgery or clinical diagnostic investigations (WADA 2026 Prohibited List, M2.2).

Key takeaways

  • It can worsen chemotherapy neuropathy. In 409 women on taxanes, 3 g/day for 24 weeks increased nerve damage, with effects measurable over two years. ASCO discourages its use for prevention.
  • Not better absorbed than L-carnitine. The one direct human comparison found lower plasma exposure, and only small rises in plasma acetylcarnitine.
  • Depression data are promising but weak. Pooled effects are large, but trials are highly inconsistent, the benefit concentrates in older adults, and publication bias is likely.
  • Alzheimer’s trials were negative. The two largest trials did not slow decline. A small positive summary effect in mild impairment rests on older trials with looser diagnostic criteria.
  • Diabetic neuropathy remains uncertain. Pain improved modestly at doses above 1,500 mg/day, but certainty is very low and the trials are linked to manufacturers.
  • The acetyl form still raises TMAO. A single 1.5 g dose raised plasma TMAO about as much as L-carnitine. Warfarin, thyroid and seizure cautions come from levocarnitine data and apply by extrapolation.

Sources

  1. National Center for Biotechnology Information. PubChem compound summaries: Acetyl-L-carnitine, CID 7045767; Levacecarnine hydrochloride, CID 2733928.
  2. Rebouche CJ. Kinetics, pharmacokinetics, and regulation of L-carnitine and acetyl-L-carnitine metabolism. Ann N Y Acad Sci. 2004;1033:30–41. PubMed.
  3. Krims-Davis K, Ozola M, Razzivina V, et al. Low Bioavailability and High TMAO Production: Novel Insights Into Acetylcarnitine and Carnitine Metabolism. Mol Nutr Food Res. 2025;69(24):e70316. PubMed.
  4. Parnetti L, Gaiti A, Mecocci P, et al. Pharmacokinetics of IV and oral acetyl-L-carnitine in a multiple dose regimen in patients with senile dementia of Alzheimer type. Eur J Clin Pharmacol. 1992;42(1):89–93. PubMed.
  5. Pennisi M, Lanza G, Cantone M, et al. Acetyl-L-Carnitine in Dementia and Other Cognitive Disorders: A Critical Update. Nutrients. 2020;12(5):1389. PubMed.
  6. Nasca C, Bigio B, Lee FS, et al. Acetyl-l-carnitine deficiency in patients with major depressive disorder. Proc Natl Acad Sci U S A. 2018;115(34):8627–8632. PubMed.
  7. Veronese N, Stubbs B, Solmi M, et al. Acetyl-L-Carnitine Supplementation and the Treatment of Depressive Symptoms: A Systematic Review and Meta-Analysis. Psychosom Med. 2018;80(2):154–159. PubMed.
  8. Kumar R, Hashempour Z, Shahriarirad S, et al. Current Evidence of Acetyl-L-Carnitine Use in Mood Disorders-: A Systematic Review and Meta-Analysis. Neuropsychiatr Dis Treat. 2026;22:586506. PubMed.
  9. Thal LJ, Carta A, Clarke WR, et al. A 1-year multicenter placebo-controlled study of acetyl-L-carnitine in patients with Alzheimer’s disease. Neurology. 1996;47(3):705–711. PubMed.
  10. Thal LJ, Calvani M, Amato A, Carta A. A 1-year controlled trial of acetyl-l-carnitine in early-onset AD. Neurology. 2000;55(6):805–810. PubMed.
  11. Hudson S, Tabet N. Acetyl-L-carnitine for dementia. Cochrane Database Syst Rev. 2003;2003(2):CD003158. PubMed.
  12. Montgomery SA, Thal LJ, Amrein R. Meta-analysis of double blind randomized controlled clinical trials of acetyl-L-carnitine versus placebo in the treatment of mild cognitive impairment and mild Alzheimer’s disease. Int Clin Psychopharmacol. 2003;18(2):61–71. PubMed.
  13. Rolim LC, da Silva EM, Flumignan RL, et al. Acetyl-L-carnitine for the treatment of diabetic peripheral neuropathy. Cochrane Database Syst Rev. 2019;6(6):CD011265. PubMed.
  14. Sima AA, Calvani M, Mehra M, et al. Acetyl-L-carnitine improves pain, nerve regeneration, and vibratory perception in patients with chronic diabetic neuropathy: an analysis of two randomized placebo-controlled trials. Diabetes Care. 2005;28(1):89–94. PubMed.
  15. Hershman DL, Unger JM, Crew KD, et al. Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for the prevention of taxane-induced neuropathy in women undergoing adjuvant breast cancer therapy. J Clin Oncol. 2013;31(20):2627–2633. PubMed.
  16. Hershman DL, Unger JM, Crew KD, et al. Two-Year Trends of Taxane-Induced Neuropathy in Women Enrolled in a Randomized Trial of Acetyl-L-Carnitine (SWOG S0715). J Natl Cancer Inst. 2018;110(6):669–676. PubMed.
  17. Loprinzi CL, Lacchetti C, Bleeker J, et al. Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline Update. J Clin Oncol. 2020;38(28):3325–3348. PubMed.
  18. Campone M, Berton-Rigaud D, Joly-Lobbedez F, et al. A double-blind, randomized phase II study to evaluate the safety and efficacy of acetyl-L-carnitine in the prevention of sagopilone-induced peripheral neuropathy. Oncologist. 2013;18(11):1190–1191. PubMed.
  19. Balercia G, Regoli F, Armeni T, et al. Placebo-controlled double-blind randomized trial on the use of L-carnitine, L-acetylcarnitine, or combined L-carnitine and L-acetylcarnitine in men with idiopathic asthenozoospermia. Fertil Steril. 2005;84(3):662–671. PubMed.
  20. Sigman M, Glass S, Campagnone J, Pryor JL. Carnitine for the treatment of idiopathic asthenospermia: a randomized, double-blind, placebo-controlled trial. Fertil Steril. 2006;85(5):1409–1414. PubMed.
  21. de Ligny W, Smits RM, Mackenzie-Proctor R, et al. Antioxidants for male subfertility. Cochrane Database Syst Rev. 2022;5(5):CD007411. PubMed.
  22. Benvenga S, Ruggeri RM, Russo A, et al. Usefulness of L-carnitine, a naturally occurring peripheral antagonist of thyroid hormone action, in iatrogenic hyperthyroidism: a randomized, double-blind, placebo-controlled clinical trial. J Clin Endocrinol Metab. 2001;86(8):3579–3594. PubMed.
  23. Caro-Ramírez JY, Franca CA, Lavecchia M, et al. Exploring the potential anti-thyroid activity of Acetyl-L-carnitine: Lactoperoxidase inhibition profile, iodine complexation and scavenging power against H(2)O(2). Experimental and theoretical studies. Spectrochim Acta A Mol Biomol Spectrosc. 2024;313:124098. PubMed.
  24. Leadiant Biosciences. Carnitor (levocarnitine) tablets, oral solution and sugar-free oral solution, prescribing information. DailyMed.
  25. World Anti-Doping Agency. The 2026 Prohibited List. WADA 2026 Prohibited List.